The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
(Q40571024)
scientific article published on April 2004
scientific article published on April 2004
Language:
Current Data About
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
other details
description | scientific article published on April 2004 |
External Links
(P356) |
10.1158/0008-5472.CAN-03-3856
|
(P698) |
15059883
|